The European Commission (EC) has reportedly charged nine pharmaceutical companies with breaches of European Union (EU) antitrust rules for entering pay-for-delay deals with generic competitors. According to a news source, the EC has in recent years increased its scrutiny of settlement agreements in which brand-name companies pay generic drug makers to delay selling their rival products. While the companies vigorously defended their actions and do not believe they are violating European competition law, the EC said that “substantial value transfers” led to abstentions from entering the market and involved direct payments, the purchase and destruction of generic products, or “guaranteed profits in a distribution agreement.” See Reuters, July 25, 2012.
Register Now As you are not an existing subscriber please register for your free daily legal newsfeed service.Register
If you have any questions about the service please contact email@example.com or call Lexology Customer Services on +44 20 7234 0606.
EU regulators charge pharma companies with antitrust violations in pay-for-delay deals
- Shook Hardy & Bacon LLP
- John D. Garretson, Patrick Henderson, Chris A. Johnson, Madeleine McDonough and Thomas T. Moga
- European Union
- August 2 2012
If you are interested in submitting an article to Lexology, please contact Andrew Teague at firstname.lastname@example.org.
“I enjoy the CLANZ newsstand and find it highly relevant to my job. I definitely have forwarded various articles to my colleagues on occasion where there is a point of general interest, particularly employment or IT law. I...
“I enjoy the CLANZ newsstand and find it highly relevant to my job. I definitely have forwarded various articles to my colleagues on occasion where there is a point of general interest, particularly employment or IT law. I really appreciate the service, it's a quick way for me to keep up to date in a way I wouldn't otherwise have time to.”